

Erratum: Current and emerging biomarkers in metastatic colorectal cancer

M.K.C. Lee MChB and J.M. Loree MD

Original Citation

Curr Oncol 2019;26:S7–15. (doi: <https://doi.org/10.3747/co.26.5719>)

Description of the Error and Correction

In the initially published manuscript, the article stated (about the BEACON clinical trial) that “Interestingly, the triplet did not appear more active than the combination of encorafenib and binimetinib (mos: 9.0 months vs. 8.4 months; HR: 0.79; 95% CI: 0.59 to 1.06).”

That was an error, because the doublet arm in BEACON used encorafenib and cetuximab. The sentence should read “Interestingly, the triplet did not appear more active than the combination of encorafenib and cetuximab (mos: 9.0 months vs. 8.4 months; HR: 0.79; 95% CI: 0.59 to 1.06).”